Transgene Biotek Past Earnings Performance
Past criteria checks 0/6
Transgene Biotek has been growing earnings at an average annual rate of 15.2%, while the Biotechs industry saw earnings growing at 12.5% annually. Revenues have been growing at an average rate of 33.4% per year.
Key information
15.2%
Earnings growth rate
15.2%
EPS growth rate
| Biotechs Industry Growth | 5.1% |
| Revenue growth rate | 33.4% |
| Return on equity | -16.8% |
| Net Margin | -980.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Transgene Biotek makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2 | -19 | 3 | 0 |
| 30 Sep 23 | 1 | -31 | 3 | 0 |
| 30 Jun 23 | 1 | -48 | 3 | 0 |
| 31 Mar 23 | 1 | -60 | 3 | 0 |
| 31 Dec 22 | 1 | -71 | 3 | 0 |
| 30 Sep 22 | 1 | -83 | 3 | 0 |
| 30 Jun 22 | 1 | -92 | 3 | 0 |
| 31 Mar 22 | 1 | -104 | 3 | 0 |
| 31 Dec 21 | 0 | -105 | 3 | 0 |
| 30 Sep 21 | 2 | -103 | 2 | 0 |
| 30 Jun 21 | 2 | -104 | 2 | 0 |
| 31 Mar 21 | 2 | -104 | 3 | 0 |
| 31 Dec 20 | 2 | -106 | 2 | 0 |
| 30 Sep 20 | 0 | -108 | 3 | 0 |
| 30 Jun 20 | 0 | -108 | 3 | 0 |
| 31 Mar 20 | 0 | -109 | 3 | 0 |
| 31 Dec 19 | 0 | -109 | 3 | 0 |
| 30 Sep 19 | 0 | -91 | 3 | 0 |
| 30 Jun 19 | 0 | -91 | 3 | 0 |
| 31 Mar 19 | 1 | -88 | 3 | 0 |
| 31 Mar 18 | 1 | -64 | 3 | 0 |
| 31 Mar 17 | 3 | -199 | 25 | 0 |
| 31 Mar 16 | 2 | -215 | 8 | 0 |
| 31 Mar 15 | 3 | -191 | 12 | 0 |
| 31 Mar 14 | 18 | -1,334 | 17 | 0 |
Quality Earnings: 526139 is currently unprofitable.
Growing Profit Margin: 526139 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 526139 is unprofitable, but has reduced losses over the past 5 years at a rate of 15.2% per year.
Accelerating Growth: Unable to compare 526139's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 526139 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.9%).
Return on Equity
High ROE: 526139 has a negative Return on Equity (-16.78%), as it is currently unprofitable.